Matches in SemOpenAlex for { <https://semopenalex.org/work/W2363118051> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2363118051 endingPage "4" @default.
- W2363118051 startingPage "720" @default.
- W2363118051 abstract "To study the therapeutic effects of different doses of botulinum toxin A (BTX-A) injection on tiptoe deformation in children with cerebral palsy.A total of 256 children with tiptoe deformation due to spastic cerebral palsy were classified into group A (muscle tension levels I-II, n=147) and group B (muscle tension levels III-IV, n=109). Group A was randomly divided into group A1 (injected with high-dose BTX-A, n=73) and group A2 (injected with low-dose BTX-A, n=74). Group B was randomly divided into group B1 (injected with high-dose BTX-A, n=55) and group B2 ( injected with low-dose BTX-A, n=54). The dose of BTX-A was 6 U/kg for groups A1 and B1 and was 3 U/kg for groups A2 and B2. Before the injection and at 1,2,6, and 12 months after injection, the muscle tension of limbs was evaluated with the modified Ashworth Scale, and the recovery of motor function of lower limbs was assessed with the Gross Motor Function Measure (GMFM).Before and after treatment, there were no significant differences in Ashworth and GMFM scores between groups A1 and A2 (P>0.05). After treatment, group B1 had a significantly reduced Ashworth score and a significantly increased GMFM score, and group B1 had a significantly lower Ashworth score and a significantly higher GMFM score compared with group B2 (P<0.05). For groups A and B, Ashworth score gradually declined post-treatment, reached the lowest point at 3 months after treatment, and returned to the level before treatment at 12 months after treatment; GMFM score gradually increased post-treatment and reached the peak level at 12 months after treatment (P<0.05).The level of muscle tension should be considered when BTX-A injection is used for treating tiptoe deformation in children with cerebral palsy. It makes no difference to use high- or low-dose BTX-A when the muscle tension level is within I-II, but high-dose BTX-A has a better performance in reducing muscle tension and improving motor function when the muscle tension level is within III-IV." @default.
- W2363118051 created "2016-06-24" @default.
- W2363118051 creator A5010298051 @default.
- W2363118051 creator A5034988905 @default.
- W2363118051 creator A5041272970 @default.
- W2363118051 creator A5054228072 @default.
- W2363118051 creator A5060384153 @default.
- W2363118051 creator A5076699095 @default.
- W2363118051 date "2014-07-01" @default.
- W2363118051 modified "2023-09-23" @default.
- W2363118051 title "[Therapeutic effects of different doses of botulinum toxin A injection on tiptoe deformation in children with cerebral palsy]." @default.
- W2363118051 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25008880" @default.
- W2363118051 hasPublicationYear "2014" @default.
- W2363118051 type Work @default.
- W2363118051 sameAs 2363118051 @default.
- W2363118051 citedByCount "1" @default.
- W2363118051 countsByYear W23631180512019 @default.
- W2363118051 crossrefType "journal-article" @default.
- W2363118051 hasAuthorship W2363118051A5010298051 @default.
- W2363118051 hasAuthorship W2363118051A5034988905 @default.
- W2363118051 hasAuthorship W2363118051A5041272970 @default.
- W2363118051 hasAuthorship W2363118051A5054228072 @default.
- W2363118051 hasAuthorship W2363118051A5060384153 @default.
- W2363118051 hasAuthorship W2363118051A5076699095 @default.
- W2363118051 hasConcept C102652120 @default.
- W2363118051 hasConcept C126322002 @default.
- W2363118051 hasConcept C1862650 @default.
- W2363118051 hasConcept C2776195251 @default.
- W2363118051 hasConcept C2777478456 @default.
- W2363118051 hasConcept C2777785397 @default.
- W2363118051 hasConcept C2778690381 @default.
- W2363118051 hasConcept C2779012798 @default.
- W2363118051 hasConcept C2779421357 @default.
- W2363118051 hasConcept C2780566999 @default.
- W2363118051 hasConcept C2988438704 @default.
- W2363118051 hasConcept C3018112276 @default.
- W2363118051 hasConcept C42219234 @default.
- W2363118051 hasConcept C71924100 @default.
- W2363118051 hasConcept C99508421 @default.
- W2363118051 hasConceptScore W2363118051C102652120 @default.
- W2363118051 hasConceptScore W2363118051C126322002 @default.
- W2363118051 hasConceptScore W2363118051C1862650 @default.
- W2363118051 hasConceptScore W2363118051C2776195251 @default.
- W2363118051 hasConceptScore W2363118051C2777478456 @default.
- W2363118051 hasConceptScore W2363118051C2777785397 @default.
- W2363118051 hasConceptScore W2363118051C2778690381 @default.
- W2363118051 hasConceptScore W2363118051C2779012798 @default.
- W2363118051 hasConceptScore W2363118051C2779421357 @default.
- W2363118051 hasConceptScore W2363118051C2780566999 @default.
- W2363118051 hasConceptScore W2363118051C2988438704 @default.
- W2363118051 hasConceptScore W2363118051C3018112276 @default.
- W2363118051 hasConceptScore W2363118051C42219234 @default.
- W2363118051 hasConceptScore W2363118051C71924100 @default.
- W2363118051 hasConceptScore W2363118051C99508421 @default.
- W2363118051 hasIssue "7" @default.
- W2363118051 hasLocation W23631180511 @default.
- W2363118051 hasOpenAccess W2363118051 @default.
- W2363118051 hasPrimaryLocation W23631180511 @default.
- W2363118051 hasRelatedWork W121797675 @default.
- W2363118051 hasRelatedWork W2105884825 @default.
- W2363118051 hasRelatedWork W2357600152 @default.
- W2363118051 hasRelatedWork W2363118051 @default.
- W2363118051 hasRelatedWork W2364263449 @default.
- W2363118051 hasRelatedWork W2364468422 @default.
- W2363118051 hasRelatedWork W2368920392 @default.
- W2363118051 hasRelatedWork W2371110366 @default.
- W2363118051 hasRelatedWork W2376537952 @default.
- W2363118051 hasRelatedWork W2884036639 @default.
- W2363118051 hasVolume "16" @default.
- W2363118051 isParatext "false" @default.
- W2363118051 isRetracted "false" @default.
- W2363118051 magId "2363118051" @default.
- W2363118051 workType "article" @default.